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The Associations of Muscle Strength, Muscle Mass, and Adiposity with Clinical 




Objective:  Sarcopenia, defined as loss of both muscle strength and mass, is associated with 
inferior clinical outcomes and quality of life (QoL) in chronic kidney disease, but its effects 
are unknown in kidney transplantation.  Obesity confers increased mortality risk and 
compromises QoL in kidney transplant recipients (KTRs), but the impacts of sarcopenic 
obesity remain unexplored.  This study aimed to evaluate the associations of muscle strength 
and mass, sarcopenia, and sarcopenic obesity with clinical outcomes and QoL in KTRs.  
 
Methods:  This prospective longitudinal study enrolled 128 KTRs ³1-year post-
transplantation.  Low muscle strength (by handgrip strength) and mass (by bio-impedance 
analysis), and a combination of both (sarcopenia) were defined as <reference cut-offs for 
corresponding indices.  Sarcopenic obesity was defined as sarcopenia combined with 
fulfilment of ³2 out of 3 criteria from 1) body mass index ³30 kg/m2, 2) bio-impedance 
analysis derived-fat mass >reference cut-offs, and 3) waist circumference >World Health 
Organisation cut-offs.  Prospective follow-up data on mortality and hospitalisation were 
collected.  QoL was evaluated using Medical Outcomes Study Short Form-36 questionnaire. 
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Results:  Median follow-up duration was 64 (60–72) months.  Low muscle strength and 
mass, sarcopenia, and sarcopenic obesity were observed in 64%, 36%, 29% and 16% of 
KTRs respectively.  Low muscle strength was independently associated with the composite 
endpoint of mortality and hospitalisation (HR=2.45; 95% CI=1.30, 4.64; p=0.006), and QoL 
(physical-related: β=-12.2; 95% CI=-23.6, -0.8; p=0.04; mental-related: β=-9.9; 95% CI=-
19.6, -0.3; p=0.04).  Low muscle mass (β=-8.8; 95% CI=-16.9, -0.8; p=0.04) and sarcopenia 
(β=-14.7; 95% CI=-27.2, -2.5; p=0.03) were associated with physical-related QoL only.  No 
independent associations were found between muscle mass, sarcopenia, and sarcopenic 
obesity with the composite outcome of mortality and hospitalisation. 
 
Conclusion:  Low muscle strength is common among KTRs, conferring poor prognosis in 
the medium term.  Future research on strength training may prove valuable in improving 
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Sarcopenia was formerly defined as age-related loss of muscle mass1,2, but has recently been 
redefined as loss of both skeletal muscle strength and mass1,3-5.  It is associated with inferior 
outcomes in quality of life (QoL)6-9, morbidity and mortality in ageing and chronic kidney 
disease (CKD) populations10-12.  Although muscle strength is commonly associated with 
muscle mass13, there may be a discordant relationship between the two muscular indices14.  
Studies in ageing and CKD populations suggest that muscle strength represents a more 
powerful prognostic index than muscle mass15,16.  Indeed, data available in the general and 
dialysis populations concluded that muscle strength per se is an important prognostic 
marker17-21. 
 
Studies on individual muscular indices (i.e. muscle strength or mass) either in isolation or in 
combination (i.e. sarcopenia) remain scarce in kidney transplantation.  The limited literature 
concludes that muscle strength is impaired in kidney transplant recipients (KTRs) compared 
with healthy individuals13.  One study revealed that low muscle strength was found in 20.5% 
of KTRs, possibly a consequence of decreased vitamin D levels and ageing22.  On the other 
hand, decreased muscle mass is a common feature in KTRs, variably attributed to the use of 
corticosteroid therapy23,24, presence of diabetes23, and suboptimal renal function13.  Low 
muscle mass at the end of the first year post-transplantation was found to associate with prior 
episodes of delayed graft function and acute rejection24.  Furthermore, decreased urinary 
creatinine excretion, a surrogate marker of low muscle mass, predicts subsequent graft loss 
and mortality in KTRs23.  However, no studies to date have scrutinised the relationships 
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between directly-measured muscular derangement categories (i.e. low muscle strength, low 
muscle mass, and sarcopenia) and clinical outcomes of kidney transplantation.   
 
Of relevance, deranged muscular indices may co-exist with obesity and weight gain, as both 
entities are highly prevalent in KTRs25.  The combination of obesity and sarcopenia is termed 
as the “sarcopenic obesity” phenotype.  Associations of sarcopenic obesity with increased 
mortality and inferior QoL have been verified in general and CKD populations26,27, but not in 
kidney transplantation.  Obesity among KTRs is known to be associated with worsened QoL, 
cardiovascular risk profiles, as well as graft and overall survival25.  It is therefore possible 
that the coexistence of obesity and muscular derangements (i.e. sarcopenic obesity) may 
aggravate these inferior outcomes. 
 
Therapeutic measures targeting muscle strength, muscle mass, sarcopenia, and sarcopenic 
obesity individually are not necessarily identical.  Therefore, greater insight into each entity 
and their clinical impacts are prerequisites for developing specific nutritional and physical 
activity interventions in KTRs.  As such, the primary objectives of this study were to 
investigate the associations of muscle strength, muscle mass, sarcopenia, and sarcopenic 
obesity with a composite endpoint of all-cause mortality and acute hospitalisation; and 
secondly, with health-related QoL, in clinically stable KTRs.   
 
Materials and Methods 
 
Study Population, Study Design, and Clinical Outcome 
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Adult KTRs beyond 1-year post-transplantation with stable graft function (i.e. defined as 
<10% increase in serum creatinine over the preceding 6 months) were consecutively recruited 
from renal transplant clinic to this single-centre prospective longitudinal study between April 
2010 and April 2013.  Written informed consent was obtained from all participants.  Detailed 
biochemical, clinical, anthropometric, dietary, lifestyle, and health-related QoL assessments 
were performed at initial study evaluation.  Following baseline assessment, all KTRs were 
prospectively followed-up in the context of research visits during routine clinic attendances 
for £84 months or until 31st March 2017, whichever event occurred first.  The endpoint of 
this study was a composite variable for a combined event, consisting of all-cause mortality, or 
the first occurrence during the study period of a non-elective hospitalisation with acute 
illness.  Exclusion criteria included episodes of acute rejection within the preceding 6 
months, evidence of sepsis in the last 6 weeks, presence of active malignancy or chronic 
infection, history of thyroid disease or adrenal insufficiency, and contraindications for use of 
bioimpedance-based body composition assessment (i.e. implanted electronic devices, metallic 
implants, amputations, pregnancy, and lactation).  This study was approved by the local 
research ethics committee and was conducted in accordance with the Declaration of Helsinki. 
 
Definitions of Low Muscle Strength, Low Muscle Mass, Sarcopenia, and Sarcopenic 
Obesity 
 
Low muscle strength was defined using gender-specific handgrip strength (HGS) cut-offs for 
low muscle strength derived from a reference population (<30 kg for men; and <20 kg for 
women)28, a definition applied in the CKD literature16.  Low muscle mass was defined as bio-
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impedance analysis derived-lean tissue index (LTI) <gender- and age- specific cut-offs 
obtained from a reference population29.  Sarcopenia was defined as concurrent presentation of 
both low HGS and low LTI3.  Sarcopenic obesity combined the criteria of sarcopenia with the 
fulfilment of ³2 out of 3 criteria from 1] body mass index (BMI) ³30 kg/m2; 2] bio-
impedance analysis derived-fat tissue index (FTI) >gender- and age- specific cut-offs 
obtained from a reference population29; and 3] central obesity, denoted as waist 
circumference >World Health Organisation (WHO) cut-offs (>102 cm for men; >88 cm for 
women)30. 
 
Data Collection at Baseline 
 
Demographic, Clinical, and Lifestyle Parameters 
 
The following demographic and clinical parameters were retrieved from patient’s medical 
records: 1] age; 2] gender; 3] ethnicity; 4] time post-transplantation; 5] presences of diabetes 
mellitus, either pre-transplantation (pre-transplantation DM) or new onset diabetes after 
transplantation (NODAT); 6] previous biopsy-proven acute rejection episodes; 7] dialysis 
vintage; 8] pre-emptive transplantation; 9] statin usage; and 10] immunosuppressive 
medication usage, either prednisolone, calcineurin inhibitor (CNI), or adjunctive 
antiproliferative agent.  Comorbidity was assessed by Index of Coexistent Disease (ICED), 
using algorithm described in the HEMO study31.  Smoking status (non-, current-, and ex- 
smoker) and alcohol consumption (units per week) were collected by questionnaire.  Physical 




Muscle Strength and Body Composition 
 
HGS (kg) was measured to the nearest 0.1kg by a digital handgrip dynamometer (Takei 
Scientific Instruments, Niigata City, Japan) with the non-dominant arm or non-fistula arm if 
previously implanted33.  Prior to measurement, participants were asked to familiarise 
themselves with the instrument and select the best adjustment.  Participants were instructed to 
stand with both arms hanging at their side and grip the dynamometer with maximum strength 
in response to a voice command.  Three trials were performed with a rest period of at least 1 
minute between each measurement, and the highest reading was noted. 
 
Body weight (kg) and height (m) were measured for derivation of BMI (kg/m2).  Waist 
circumference (cm) was determined using methodology recommended by the WHO30.  Body 
composition was assessed by a well-validated multi-frequency bio-impedance based body 
composition monitor (BCM, Fresenius Medical Care, Germany)34, providing measurements 
of lean tissue mass (LTM, kg) and fat mass (FM, kg).  Both measurements were normalised 




Dietary intakes encompassing total energy (kcal/day) and protein (g/day) intakes were 
estimated by a 3-day food diary, a widely accepted dietary assessment tool deemed to be 
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valid, reliable, and accurate in estimating typical and habitual nutrient intake35.  Nutritional 




Blood samples were taken in the morning following an overnight fast for measurements of 
creatinine, estimated glomerular filtration rate (eGFR) derived using four-variable 
modifications of diet in renal disease equation, haemoglobin (Hb), and vitamin D (25-
hydroxyvitamin D).  Analyses were undertaken in the accredited hospital biochemistry 
laboratory.  High-sensitivity C-reactive protein (hsCRP) was measured using a Tina-quant® 
cardiac C-reactive protein latex high-sensitive immunoturbidimetric assay (Roche 
Diagnostics, Switzerland). 
 
Health-related Quality of Life 
 
Health-related QoL was assessed using the well-validated Medical Outcomes Study Short 
Form-36 questionnaire (SF-36)36, providing scores for physical- and mental- health-related 





Statistical analyses were performed using SPSS Statistics 23 (Chicago, IL).  Descriptive 
statistics were used to examine baseline characteristics.  Results were presented as mean ± 
standard deviation (SD) or median with interquartile range (IQR).  Comparison between two 
groups were performed using independent-samples t-test, Wilcoxon rank-sum test, or Fisher’s 
Exact test.  Pearson (r) or Kendall’s Tau (t) correlations were used to assess relationships.  
Survival analysis of time to occurrence of composite outcome (all-cause mortality, or first 
acute hospitalisation) was conducted using Cox proportional hazards regression model and 
Kaplan-Meier method evaluated by log-rank test.  Linear regression analyses were used to 
determine associations between predictor variables and health-related QoL.  Relationships 
established by Cox proportional hazards and linear regressions were expressed as hazard ratio 
(HR) and beta coefficient (β) respectively, with 95% confidence interval (CI).  A type 1 error 
rate ≤5% (p≤0.05) was considered significant. 
 
Measures of muscular parameters (HGS and LTI), adiposity (BMI, FTI, and waist 
circumference), and categorical/composite indices (low muscle strength, low muscle mass, 
sarcopenia, and sarcopenic obesity) were assessed individually in separate regression analysis 
due to possibility of collinearity among these highly correlated variables, as shown in 
Supplementary Material, Tables 1a and 1b.  While the categorical/composite variables 
were examined on categorical scale, all muscular and adiposity measures were assessed on 
both continuous and categorical scales.  Each index was evaluated in three discrete Cox or 
linear regression models.  Model 1 adjustments were made for socio-demographic variables 
including age, gender, ethnicity, smoking status, and alcohol consumption.  In model 2, 
adjustments were made for variables in model 1 plus clinically relevant variables 
encompassing ICED, diabetes status, eGFR, dialysis vintage, pre-emptive transplantation, 
time post-transplantation, acute rejection episodes, use of statin, and use of CNI, or 
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adjunctive antiproliferative agent, or prednisolone.  Finally, model 3 were adjusted for 
variables in models 1 and 2, plus potential mediators including SGA score, physical activity 
level, vitamin D, Hb, hsCRP, dietary intakes of protein and energy. 
 
Further exploratory analyses were performed to identify the predictors of HGS.  Plausible 
socio-demographic, clinical, biochemical, lifestyle, and dietary parameters were assessed as 
potential explanatory variables.  Linear regression analyses were performed in 2 stages.  
Initially, the effect of each variable was assessed in a series of univariate analyses.  
Subsequently, the joint effect of variables was examined in a multivariate analysis including 
only the explanatory variables with univariate association of p<0.20.  A backward selection 







Of 138 patients approached, 10 did not participate due to work commitment (93% consent 
rate).  Mean age was 49±15 years; 56% was male; 78% was Caucasian; median time post-
transplantation was 5 (2–11) years; and mean eGFR was 45±18 mL/min/1.73m2.  Table 1 
indicates the baseline characteristics of the entire study population and stratified according to 
normal or low muscle strength.  KTRs with low muscle strength were older (p=0.008), 
presented with longer transplant (p=0.005) and dialysis (p=0.04) vintage, and more likely to 
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receive prednisolone (p=0.002).  In addition, decreased physical activity level (p=0.04), 
lower circulating concentrations of Hb (p=0.04) and vitamin D (p=0.001), reduced dietary 
protein intake (p=0.04), decreased LTI (p=0.002), and increased FTI (p=0.04) were observed 
in KTRs with low muscle strength. 
 
Median prospective follow-up duration was 64 (60–72) months.  Crude rates of mortality and 
hospitalisation were 10% and 47% respectively.  Low muscle strength and mass were evident 
in 82 and 46 patients (64% and 36%) respectively.  Concurrent presentation of low muscle 
strength and mass, i.e. sarcopenia, were present in 37 patients (29%).  Obesity, determined by 
fulfilling ³2 out of 3 criteria from BMI, FTI, and waist circumference measurements, was 
found in 52 patients (41%).  Sarcopenic obesity, based on sarcopenia combined with obesity, 
was found in 20 patients (16%).   
 
Associations of Muscle Strength and Mass, Sarcopenia, and Sarcopenic Obesity with the 
Risk of Mortality and First Acute Hospitalisation 
 
A composite endpoint of time to death or first acute hospitalisation was modelled as the 
outcome of interest.  Hospitalisation attributed to kidney transplant dysfunction were 
excluded.  During follow-up, mortality and hospitalisation rates were 10% (n=13) and 47% 
(n=60) respectively.  Causes of death were malignancy (n=4), acute ischaemic cardiac events 
(n=4), heart failure (n=3), stroke (n=1), and sepsis (n=1).  Causes of hospitalisation were 
sepsis (40%, n=51), acute ischaemic cardiac events (4%, n=5), and gastro-intestinal infection 
(3%, n=4).    
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Univariate Cox associations of muscular, adiposity, categorical/composite indices, and 
relevant covariates with combined mortality and hospitalisation risk are shown in 
Supplementary Material, Tables 2a and 2b.   
 
When the muscular and adiposity indices were analysed as continuously-distributed measures 
in multivariate Cox regression analyses, shown in Table 2, only decreased HGS displayed 
significant association with higher risk of combined mortality and hospitalisation in all 
adjusted models (models 1, 2 and 3).  Although lower LTI demonstrated significant adjusted 
association with higher risk of combined mortality and hospitalisation in models 1 and 2, the 
association did not persist in model 3 when further adjustment was made.  No association was 
found between adiposity measures (BMI, FTI, and waist circumference) and combined 
mortality and hospitalisation risk in all adjusted models. 
 
In the multivariate Cox regression analyses pertaining categorical/composite indices (Table 
2), only low muscle strength revealed significant association with higher risk of combined 
mortality and hospitalisation in all adjusted models.  In fact, the risk is almost 2.5 times 
higher in KTRs presented with low muscle strength compared to those with normal muscle 
strength (HR=2.45; 95% CI=1.30, 4.64; p=0.006).  Kaplan-Meier survival estimates depicted 
higher rate of combined mortality and hospitalisation in KTRs with low muscle strength, as 
shown in Figure 1 (p<0.01).  Although low muscle mass, sarcopenia, and sarcopenic obesity 
showed significant adjusted associations with combined mortality and hospitalisation risk in 
model 1, these associations were not retained with further adjustment in models 2 and 3.  No 
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adjusted association was found between obesity and the combined endpoint of mortality and 
hospitalisation. 
 
Associations of Muscle Strength and Mass, Sarcopenia, and Sarcopenic Obesity with 
Health-related Quality of Life 
 
Mean summary scores for SF-36 physical- and mental- health-related QoL were 62±25 and 
69±22 respectively.  The scores were normally distributed and were analysed on the original 
scale.  Univariate linear associations of muscular, adiposity, categorical/composite indices, 
and relevant covariates with physical- and mental- health-related QoL are shown in 
Supplementary Material, Tables 3a-3d. 
 
When all the muscular and adiposity measures were analysed on continuous scale in the 
multivariate linear regression analyses, only increased HGS was associated with 
improvements in both physical- (Table 3a) and mental- (Table 3b) health-related QoL in all 
adjusted models, illustrated in Figure 2.  While increased LTI revealed significant 
association with improving physical health-related QoL in all adjusted models, its positive 
association with mental health-related QoL was only apparent in models 1 and 2, and this 
association failed to persist in the fully adjusted model.  None of the adiposity measures were 
associated with physical- and mental- health-related QoL. 
 
When all categorical/composite indices were examined as categorical variables individually 
in the multivariate linear regression analysis, only low muscle strength were associated with 
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reductions in both physical- (Table 3a) and mental- (Table 3b) health-related QoL in all 
adjusted models.  While low muscle mass and sarcopenia were associated with decreased 
physical health-related QoL in all adjusted models, their independent associations with 
reduced mental health-related QoL were only observed in models 1 and 2, and these 
associations were not retained in the fully adjusted model.  Finally, neither obesity nor 
sarcopenic obesity were associated with physical- and mental- health-related QoL in all 
adjusted models. 
 
Predictors of Muscle Strength 
 
Further exploratory analyses were performed to identify the predictors of HGS, justified by 
the independent clinical impacts of HGS on mortality, morbidity, and health-related QoL; and 
the clinical relevance of identifying modifiable measures for improving HGS. 
 
The univariate and multivariate analyses showing the predictors of HGS are indicated in 
Table 4.  In the adjusted model, higher LTI, younger age, male gender, increased Hb and 
vitamin D concentrations, higher physical activity level, and increased protein intake were 
identified as independent predictors for increased HGS.  Of note, a substantial proportion of 






This study revealed that low muscle strength is common among a prevalent cohort of 
clinically stable KTRs.  Importantly, only decreased muscle strength was identified as an 
independent risk factor for a composite endpoint of all-cause mortality and morbidity, as well 
as health-related QoL.  Muscle mass, sarcopenia, and sarcopenic obesity did not demonstrate 
meaningful prognostic impact in this study.   
 
This study addresses two important phenomena.  Firstly, muscle strength per se was found to 
be an important prognostic marker, affirming the emerging data from the general, other 
diseased, and non-transplant CKD populations17-21.  Secondly, muscle strength demonstrated 
superiority over muscle mass in predicting the composite outcome of mortality and 
morbidity, as well as health-related QoL, a conclusion similarly drawn from both healthy and 
diseased populations15,16,23,37.  The latter finding may be justified by the additional qualitative 
data derived from muscle strength evaluation that was not captured by muscle mass 
assessment, such as muscle quality, health and excitability38,39. 
 
In particular, a previous study showed that lower urinary creatinine excretion, a proxy for 
reduced muscle mass, was associated with increased mortality in KTRs23.  This finding is in 
contrast to the current investigation where no predictive association was found between 
muscle mass and the composite outcome of mortality and morbidity.  Although the present 
study may be hampered by a relatively short follow-up duration, it provides a direct 
estimation of muscle mass using bio-impedance analysis, a methodology for muscle mass 
measurement that demonstrated higher correlation with dual energy x-ray absorptiometry (i.e. 
the gold standard) compared with urinary creatinine excretion39.  Of relevance, a prior study 
in non-transplant CKD supported the findings of this study, by which muscle mass assessed 
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using bio-impedance analysis was not predictive of mortality39.  Instead, reduced urinary 
creatinine excretion was found to be a predictor of death independent of bio-impedance 
analysis-derived muscle mass.  The authors speculated that urinary creatinine excretion may 
capture information about muscle quality independently of muscle mass e.g. creatine 
content39, suggesting that other muscular factors such as muscle function and muscle 
metabolism may play important roles in driving clinical outcomes.  This reasoning 
corroborates the findings of the present study showing that muscle strength was predictive of 
all-cause mortality and morbidity irrespective of quantities of muscle mass.   
 
Of importance, the findings from this study implies causal relationships of muscle strength 
with clinical outcomes and health-related QoL, justifying interventional strategies to improve 
muscle strength in KTRs.  Whilst such relationships cannot be confirmed with the current 
observation data, other investigations have provided tantalising mechanistic pathways.  An 
intriguing body of literature has emerged over the past decade in relation to soluble mediators 
released from contracting skeletal muscles particularly during exercise, termed as 
“myokines”40-42, including interleukin (IL)-5, brain-derived neurotropic factor, irisin, 
gelsolin, and IL-6.  These myokines are known to possess potent anti-inflammatory, 
antioxidant, and cytoprotective properties, exerting pleotropic modulating effects in 
metabolic and cardiovascular diseases40-42.  Although studies conducted in the general, CKD 
and kidney transplant populations showed that resistance training confers positive changes on 
cardiovascular risk profiles43-45, real-life translational improvement in mortality and 
morbidity are yet to be observed.  Additionally, the associations between increased muscle 
strength and improved mental health-related QoL may be explained by the irisin-mediated 
muscle-brain crosstalk, supported by the proposed upstream effect at the level of central 
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nervous system46.  Indeed, studies from the general population affirm that strength training 
improves specifically the mental aspects of QoL47.   
 
The current study found that decreased muscle strength, decreased muscle mass, and 
sarcopenia were all independently associated with inferior physical health-related QoL.  This 
is because muscle strength and mass are intuitively required to perform physical activities 
measured by the SF-36 physical functioning.  In support of this, studies conducted in the 
ageing, CKD and kidney transplant populations showed that resistance training can improve 
muscle strength and mass, physical capacity, overall- and physical- health-related QoL43,44,48. 
 
Increased muscle mass, higher concentrations of vitamin D and Hb, increased physical 
activity level, and higher protein intake were identified as modifiable independent predictors 
of increased muscle strength in this study.  The positive correlation between muscle mass and 
strength has been well-established.  However, it is important to note that higher muscle mass 
may not necessarily translate into greater muscle strength, and gains in muscle strength may 
be achieved without corresponding increases in muscle mass.  It is therefore crucial to 
consider other lifestyle modifications beyond enhancing muscle mass.  Studies in the general 
population showed that promoting physical activity through resistance training with protein 
supplementation may increase muscle mass and strength49.  Vitamin D deficiency and 
anaemia are both common among KTRs.  Literature in general50 and CKD51 populations 
indicated that vitamin D supplementation may improve muscle mass and strength, especially 
those with vitamin D deficiency50.  Although the exact mechanisms have not been fully 
elucidated, it is postulated that the biologically active form of vitamin D binds to the vitamin 
D receptors located on skeletal muscle fibres, triggering de novo protein synthesis within the 
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muscle, possibly resulting in changes in muscle cell morphology and hence overall muscular 
performance52.  Lastly, literature in the general population revealed an association between 
lower Hb levels and reduced muscle strength, particularly in the presence of anaemia53, 
possibly with resultant decreased muscular tissue oxygenation ultimately manifesting as 
reduced muscular strength53.  This implicates the correction of anaemia in KTRs as a 
potential means for improving muscle strength.  Other possible factors influencing muscular 
strength should be considered, including muscle fibre type and contractility, the architectural 
arrangement of muscle fibres, muscle aerobic capacity, neuromuscular activation, and 
presence of intermuscular adipose tissue and muscle fibrosis38.  Although these potential 
underlying mechanisms are beyond the scope of this study, findings from the current study 
should be considered as hypothesis-generating prequels to future research to elucidate the 
pathogenesis of reduced muscle strength at tissue level. 
 
Notably, the prevalence of obesity (i.e. 41%) in this study remains comparable to the current 
literature25,54,55, yet only 16% of KTRs fulfilled the criteria of sarcopenic obesity.  In contrast 
to muscle strength, measures of adiposity and the composite phenomenon of sarcopenic 
obesity failed to demonstrate associations with clinical outcomes and health-related QoL.  
These findings are in partial agreement with Kovesdy, et al., where no association was 
evident between BMI and mortality in KTRs56.  The authors postulated that the “obesity 
paradox” observed in multiple chronic diseases including CKD may in part be responsible for 
this association.  However, Kovesdy, et al., found an association between mortality and 
central obesity measured by waist circumference56, which differs from the results of this 
study.  Whilst this discrepancy may be attributed to differences in patient characteristics of 
the study cohorts, the importance of central and generalised obesity should not be dismissed, 
as their adverse effects on kidney transplant outcomes tend to be reported in cohorts with 
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longer transplant vintage and follow-up duration.  Nevertheless, it is crucial to highlight the 
emerging clinical importance of muscular indices, particularly muscle strength, in the 
medium term.  Future evaluations should incorporate concurrent measurements of muscular 
and adiposity indices in resemblance to the methodology in the current study, aiming to 
dissect their relative importance and contributions to various clinical outcomes. 
 
Although this study presents the first compelling association between decreased muscle 
strength and adverse clinical outcomes in kidney transplantation, it is hampered by a small 
sample size in a single centre.  The inherent observational nature of the study precludes the 
establishment of causality between muscle strength and clinical outcomes.   Further 
validations with prospective clinical trials are required to elucidate the potential beneficial 
effects of strength training in KTRs, thereby circumventing the confounding role of muscle 
strength in the co-morbidities that may directly impact on clinical outcome.   Such studies 
should involve exercise interventions, incorporating resistance training and possibly 
adjunctive nutritional supplementation such as protein and vitamin D supplements.   
 
In conclusion, this study shows that low muscle strength represents a common and clinically 
relevant problem in an otherwise stable kidney transplant population.  Muscle strength 
assessment in routine clinical practice may serve as a novel tool for improving risk 
stratification in prevalent KTRs.  Future clinical trials should evaluate the effectiveness of 
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Table 1:  Baseline Population Characteristics 
 
 All KTRs 
(n = 128) 
KTRs with Normal 
Muscle Strength 
(n = 46) 
 
KTRs with Low 
Muscle Strength 
(n = 82) 
*p-value 
Demographic & Lifestyle Parameters 
 
†Mean age (years) 
 
49 ± 15 45 ± 14 52 ± 15 0.008 
Gender (male, %) 
 
56 48 62 0.15 
aEthnicity (%): 
Caucasian 















‡Median time post-transplantation (years) 
 
5 (2 – 11) 3 (1 – 7) 6 (2 – 14) 0.005 























‡Median alcohol intake (units/week) 
 
3 (2 – 5)  3 (2 – 5) 3 (2 – 6) 0.95 
†Mean physical activity level (hours/week) 
 
14 ± 5 16 ± 6 13 ± 4 0.04 
Clinical Parameters 
 
Pre-emptive transplantation (%) 
 
22 28 18 0.20 
‡Median Dialysis vintage (years) 
 
2 (1 – 4) 1 (1 – 3) 2 (1 – 5) 0.04 
‡Median ICED score 
 
2 (2 – 2) 2 (2 – 2) 2 (2 – 2) 0.37 






















Previous acute rejection episodes (%) 
 
9 12 8 0.54 
Statin usage (%) 
 
55 56 54 0.98 
Immunosuppressive medication usage (%): 
Prednisolone 
CNI 


















Dosage of immunosuppressive medications (mg/day): 
‡Median dose of Prednisolone 
‡Median dose of Tacrolimus 
‡Median dose of Cyclosporin 
‡Median dose of Mycophenolate Mofetil 
‡Median dose of Azathioprine 
 
 
5 (5 – 5) 
4.0 (2.5 – 7.4) 
150 (150 – 200) 
1000 (1000 – 1500) 
100 (50 – 100) 
 
5 (5 – 5) 
3.8 (2.0 – 5.5) 
150 (140 – 200) 
1000 (735 – 1220) 
75 (50 – 100) 
 
5 (5 – 5) 
5.0 (3.0 – 8.0) 
150 (150 – 200) 
1000 (1000 – 1500) 










†Mean eGFR (mL/min/1.73m2) 
 
45 ± 18 47 ± 18 44 ± 18 0.47 
‡Median hsCRP (mg/L) 
 
2.47 (1.00 – 4.89) 2.00 (0.79 – 5.50) 2.67 (1.10 – 4.48) 0.42 
†Mean Hb (g/dL) 
 
12.7 ± 1.6 13.0 ± 1.7 12.5 ± 1.4 0.04 
‡Median 25-hydroxyvitamin D (nmol/L) 
 
40 (22 – 64) 60 (29 – 82) 35 (20 – 53) 0.001 
Anthropometry, Nutritional Status & Body Composition Parameters 
 
†Mean BMI (kg/m2) 28.1 ± 5.7 
 
27.6 ± 5.5 28.4 ± 5.9 0.46 
‡Median SGA score 7 (7 – 7)  
 
7 (7 – 7) 7 (6 – 7) 0.10 
†Mean waist circumference (cm) 98 ± 17  
 
95 ± 17 100 ± 16 0.09 
†Mean HGS (kg) 24.4 ± 9.3  
 
30.3 ± 9.6 20.7 ± 6.8 <0.001 
Bio-impedance measurements (kg/m2): 
†Mean LTI (kg/m2) 
†Mean FTI (kg/m2) 
 
14.1 ± 2.9  
13.8 ± 6.3 
 
 
15.1 ± 3.0 
12.4 ± 5.6 
 
13.4 ± 2.7 




Dietary Intake Parameters 
 
†Mean protein intake (g/kg/day) 
†Mean energy intake (kcal/kg/day) 
 
1.10 ± 0.16 
34 ± 8 
 
1.25 ± 0.17 
36 ± 9 
1.01 ± 0.16 
33 ± 7 
0.04 
0.20 
*Comparison between KTRs with normal and low muscle strength. 
 
†Normally distributed data, results expressed as mean ± standard deviation. 
 ‡Non-normally distributed data, results expressed as median with interquartile range. 
 
aFor the purpose of statistical analysis, the ethnicity of patients classified as Afro-Caribbean (5 %), Asian (15 %), and others (2 %) was grouped as “Non-
Caucasian” (22 %). 
 
Abbreviations:  BMI = Body Mass Index; CNI = Calcineurin Inhibitor; eGFR = estimated Glomerular Filtration Rate; FTI = Fat Tissue Index; Hb = 
haemoglobin; HGS = Handgrip Strength; hsCRP = high-sensitivity C-Reactive Protein; ICED = Index of Coexistent Disease; LTI = Lean Tissue Index; 
NODAT = New Onset Diabetes After Transplantation; Pre-transplantation DM = Pre-transplantation Diabetes Mellitus; KTRs = Kidney Transplant 
Recipients; SGA = Subjective Global Assessment. 
Table 2:  Adjusted Associations of Muscular, Adiposity, and Composite Indices with the Risk of Mortality and Acute Hospitalisation 
 
 *Model 1 
 
**Model 2 ***Model 3 
Multivariate Cox Regression 
 
Multivariate Cox Regression Multivariate Cox Regression 
HR (95% CI) 
 
p-value HR (95% CI) p-value HR (95% CI) p-value 




0.93 (0.90, 0.97) <0.001 0.92 (0.89, 0.97) <0.001 0.95 (0.90, 0.99) 0.03 
LTI (kg/m2) 
 
0.89 (0.80, 0.99) 0.03 0.87 (0.75, 0.99) 0.04 0.88 (0.74, 1.02) 0.12 
BMI (kg/m2) 
 
1.02 (0.98, 1.07) 0.36 1.01 (0.96, 1.07) 0.66 1.01 (0.92, 1.09) 0.65 
FTI (kg/m2) 
 
1.03 (0.99, 1.08) 0.15 1.04 (0.99, 1.09) 0.16 1.02 (0.96, 1.08) 0.55 
Waist Circumference (cm) 
 
1.01 (0.99, 1.02) 0.51 1.01 (0.99, 1.02) 0.74 1.00 (0.97, 1.03) 0.97 
Categorical and Composite Indices (Categorical Scale) 
 
aLow Muscle Strength 
 
3.63 (2.16, 6.21) <0.001 3.07 (1.71, 5.51) <0.001 2.45 (1.30, 4.64) 0.006 
bLow Muscle Mass 
 
2.09 (1.10, 4.12) 0.02 1.78 (0.98, 3.67) 0.08 1.01 (0.62, 1.85) 0.19 
cSarcopenia 
 
1.94 (1.10, 3.42) 0.02 1.76 (0.89, 3.48) 0.10 1.58 (0.69, 3.60) 0.28 
dObesity 
 
1.31 (0.83, 2.06) 0.25 1.14 (0.69, 1.88) 0.35 1.15 (0.70, 1.80) 0.44 
eSarcopenic Obesity 
 
2.36 (1.20, 4.63) 0.02 2.24 (0.99, 4.96) 0.08 1.89 (0.67, 5.37) 0.23 
*Model 1:  Adjusted for age, gender, ethnicity, smoking status, and alcohol consumption. 
**Model 2:  Adjusted for variables in model 1 plus ICED, diabetes status (non-diabetic or pre-transplantation DM or NODAT), eGFR, dialysis vintage, pre-emptive transplantation, time 
post transplantation, acute rejection episodes, use of statin, and use of CNI or adjunctive antiproliferative agent or prednisolone. 
***Model 3:  Adjusted for variables in models 1 and 2 plus SGA score, physical activity level, vitamin D, Hb, hsCRP, and dietary intakes of protein and energy. 
 
aLow Muscle Strength, defined as HGS < Reference Cut-offs. 
bLow Muscle Mass, defined as LTI < Reference Cut-offs. 
cSarcopenia, defined as both HGS and LTI < Reference Cut-offs. 
dObesity, defined as fulfillment of ³ 2 out of 3 criteria from BMI ³ 30kg/m2, FTI > Reference Cut-offs, and Waist Circumference > WHO Cut-offs. 
eSarcopenic Obesity, defined as a combination of sarcopenia and obesity. 
 
Abbreviations:  BMI = Body Mass Index; CI = Confidence Interval; CNI = calcineurin inhibitor; eGFR = estimated Glomerular Filtration Rate; FTI = Fat Tissue Index; Hb = 
Haemoglobin; HR = Hazard Ratio; HGS = Handgrip Strength; hsCRP = high-sensitivity C-Reactive Protein; ICED = Index of Coexistent Disease; LTI = Lean Tissue Index; NODAT 
= New Onset Diabetes After Transplantation; Pre-transplantation DM = Pre-transplantation Diabetes Mellitus; SGA = Subjective Global Assessment; WHO = World Health 
Organisation. 
 
Table 3a:  Adjusted Associations of Muscular, Adiposity, and Composite Indices with Physical Health-related Quality of Life 
 
 *Model 1 
 
**Model 2 ***Model 3 
Linear Regression 
 
Linear Regression Linear Regression 
b (95% CI) 
 
p-value b (95% CI) p-value b (95% CI) p-value 




1.7 (1.2, 2.3) 0.001 1.6 (1.1, 2.3) 0.001 1.6 (0.9, 2.4) 0.001 
LTI (kg/m2) 
 
1.2 (0.5, 1.9) 0.001 1.2 (0.5, 1.9) 0.005 1.1 (0.4, 1.8) 0.03 
BMI (kg/m2) 
 
-0.2 (-0.9, 0.6) 0.69 -0.3 (-1.2, 0.6) 0.67 -0.4 (-1.6, 0.9) 0.66 
FTI (kg/m2) 
 
-0.3 (-1.1, 0.4) 0.41 -0.1 (-0.8, 0.7) 0.48 -0.7 (-1.7, 0.4) 0.51 
Waist Circumference (cm) 
 
-0.1 (-3.0, 3.1) 0.39 -0.1 (-2.9, 3.2) 0.42 -0.2 (-0.6, 0.2) 0.58 
Categorical and Composite Indices 
 
aLow Muscle Strength 
 
-17.9 (-27.1, -8.7) 0.001 -16.5 (-26.2, -6.7) 0.001 -12.2 (-23.6, -0.8) 0.04 
bLow Muscle Mass 
 
-11.5 (-20.5, -2.4) 0.01 -10.3 (-18.2, -2.3) 0.03 -8.8 (-16.9, -0.8) 0.04 
cSarcopenia 
 
-18.8 (-31.4, -6.2) 0.004 -14.1 (-23.6, -4.6) 0.004 -14.7 (-27.2, -2.5) 0.03 
dObesity 
 
-3.9 (-12.2, 4.4) 0.36 -1.2 (-10.2, 7.7) 0.48 -0.9 (-11.3, 12.5) 0.41 
eSarcopenic Obesity 
 
-12.9 (-26.1, 0.3) 0.06 -11.7 (-27.8, 4.5) 0.15 -5.7 (-26.9, 15.4) 0.59 
*Model 1:  Adjusted for age, gender, ethnicity, smoking status, and alcohol consumption. 
**Model 2:  Adjusted for variables in model 1 plus ICED, diabetes status (non-diabetic or pre-transplantation DM or NODAT), eGFR, dialysis vintage, pre-emptive transplantation, time post 
transplantation, acute rejection episodes, use of statin, and use of CNI or adjunctive antiproliferative agent or prednisolone. 
***Model 3:  Adjusted for variables in models 1 and 2 plus SGA score, physical activity level, vitamin D, Hb, hsCRP, and dietary intakes of protein and energy. 
 
aLow Muscle Strength, defined as HGS < Reference Cut-offs. 
bLow Muscle Mass, defined as LTI < Reference Cut-offs. 
cSarcopenia, defined as both HGS and LTI < Reference Cut-offs. 
dObesity, defined as fulfillment of ³ 2 out of 3 criteria from BMI ³ 30kg/m2, FTI > Reference Cut-offs, and Waist Circumference > WHO Cut-offs. 
eSarcopenic Obesity, defined as a combination of sarcopenia and obesity. 
 
Abbreviations:  b = beta coefficient; BMI = Body Mass Index; CI = Confidence Interval; CNI = calcineurin inhibitor; eGFR = estimated Glomerular Filtration Rate; FTI = Fat Tissue Index; 
Hb = Haemoglobin; HGS = Handgrip Strength; hsCRP = high-sensitivity C-Reactive Protein; ICED = Index of Coexistent Disease; LTI = Lean Tissue Index; NODAT = New Onset Diabetes 
After Transplantation; Pre-transplantation DM = Pre-transplantation Diabetes Mellitus; SGA = Subjective Global Assessment; WHO = World Health Organisation. 
Table 3b:  Adjusted Associations of Muscular, Adiposity, and Composite Indices with Mental Health-related Quality of Life 
 
 *Model 1 
 
**Model 2 ***Model 3 
Linear Regression 
 
Linear Regression Linear Regression 
b (95% CI) 
 
p-value b (95% CI) p-value b (95% CI) p-value 




1.2 (0.7, 1.6) 0.001 1.1 (0.5, 1.6) 0.001 0.8 (0.2, 1.5) 0.01 
LTI (kg/m2) 
 
1.5 (1.0, 2.1) 0.002 1.1 (0.7, 1.6) 0.02 0.8 (-0.1, 1.8) 0.08 
BMI (kg/m2) 
 
0.4 (-0.3, 1.1) 0.06 0.8 (-0.1, 1.7) 0.10 0.1 (-1.1, 1.1) 0.68 
FTI (kg/m2) 
 
0.2 (-0.4, 0.8) 0.63 0.4 (-0.3, 1.1) 0.66 -0.3 (-1.2, 0.6) 0.68 
Waist Circumference (cm) 
 
0.2 (-0.1, 0.4) 0.18 0.2 (-0.1, 0.5) 0.19 -0.1 (-0.5, 0.3) 0.63 
Categorical and Composite Indices 
 
aLow Muscle Strength 
 
-11.1 (-19.7, -2.6) 0.01 -10.6 (-18.7, -2.5)  0.01 -9.9 (-19.6, -0.3) 0.04 
bLow Muscle Mass 
 
-10.3 (-18.1, -2.6) 0.01 -8.2 (-15.7, -0.5) 0.04 -1.1 (-11.2, 8.9) 0.21 
cSarcopenia 
 
-13.2 (-23.2, -3.2) 0.02 -12.6 (-23.6, -1.6) 0.03 -7.4 (-20.6, 5.8) 0.26 
dObesity 
 





-7.9 (-20.9, 5.1) 0.23 -4.3 (-18.2, 9.7) 0.54 -2.2 (-20.1. 15.5) 0.68 
*Model 1:  Adjusted for age, gender, ethnicity, smoking status, and alcohol consumption. 
**Model 2:  Adjusted for variables in model 1 plus ICED, diabetes status (non-diabetic or pre-transplantation DM or NODAT), eGFR, dialysis vintage, pre-emptive transplantation, time post transplantation, acute 
rejection episodes, use of statin, and use of CNI or adjunctive antiproliferative agent or prednisolone. 
***Model 3:  Adjusted for variables in models 1 and 2 plus SGA score, physical activity level, vitamin D, Hb, hsCRP, and dietary intakes of protein and energy. 
 
aLow Muscle Strength, defined as HGS < Reference Cut-offs. 
bLow Muscle Mass, defined as LTI < Reference Cut-offs. 
cSarcopenia, defined as both HGS and LTI < Reference Cut-offs. 
dObesity, defined as fulfillment of ³ 2 out of 3 criteria from BMI ³ 30kg/m2, FTI > Reference Cut-offs, and Waist Circumference > WHO Cut-offs. 
eSarcopenic Obesity, defined as a combination of sarcopenia and obesity. 
 
Abbreviations:  b = beta coefficient; BMI = Body Mass Index; CI = Confidence Interval; CNI = calcineurin inhibitor; eGFR = estimated Glomerular Filtration Rate; FTI = Fat Tissue Index; Hb = Haemoglobin; 
HGS = Handgrip Strength; hsCRP = high-sensitivity C-Reactive Protein; ICED = Index of Coexistent Disease; LTI = Lean Tissue Index; NODAT = New Onset Diabetes After Transplantation; Pre-transplantation 
DM = Pre-transplantation Diabetes Mellitus; SGA = Subjective Global Assessment; WHO = World Health Organisation. 
 
Table 4:  Predictors of Muscle Strength (Handgrip Strength) in Kidney Transplant Recipients 
 
 Univariate Linear Regression Analysis 
 
Multivariate Linear Regression Analysis* 
b (95% CI) 
 
p-value b (95% CI) 
 
p-value 




2.3 (1.9, 2.7) <0.001 1.9 (1.4, 2.5) <0.001 
FTI (kg/m2) 
 
-0.2 (-0.5, 0.1) 0.07   
Waist circumference (cm) 
  
0.2 (-0.3, 0.8) 0.10   
BMI (kg/m2) 
 
0.3 (0.1, 0.6) 0.04   
Demographic and Lifestyle Parameters 
 
†Age (years) -1.2 (-2.2, -0.1) 0.01 
 




























-2.5 (-6.1, 1.1) 





















-0.2 (-4.8, 4.4) 











†Dialysis vintage (years) 
 
-0.2 (-4.4, 4.1) 0.22   
Pre-emptive transplantation 1.7 (-2.2, 5.6) 0.20  
 
 
†Time post transplantation (years) 
 
-2.4 (-4.7, -0.1) 0.04   
Acute rejection episodes 
 




Adjunctive antiproliferative agent 
 
 
-5.9 (-11.4, -0.4) 
-3.2 (-7.1, 0.7) 










Use of statin 
 












-0.4 (-2.7, 1.9) 0.76   
Hb (g/dL) 
 




†Vitamin D (nmol/L) 
 








3.4 (1.4, 5.3) 0.001   
Physical activity level (hours/week) 
 




†Protein intake (g/day) 
 
1.7 (1.2, 2.3) 0.01 1.0 (0.5, 1.6) 0.04 
‡Energy intake (kcal/day) 
 
0.4 (0.1, 0.7) 0.04   
 
Adjusted R2 63% 
 
*Results in the final multivariate linear regression model were presented.   
§For the purpose of statistical analysis, the ethnicity of patients classified as “Afro-Caribbean”, “Asian”, and “others” was grouped as “Non-Caucasian”; 78 % 
“Caucasian” verses 22 % “Non-Caucasian”.   
†b reported for a 10-unit increase in explanatory variable.  ‡b reported for a 100-unit increase in explanatory variable. 
Abbreviations:  b = beta coefficient; BMI = Body Mass Index; CI = Confidence Interval; CNI = Calcineurin Inhibitor; eGFR = estimated Glomerular Filtration Rate; 
FTI = Fat Tissue Index; Hb = Haemoglobin; hsCRP = high-sensitivity C-Reactive Protein; ICED = Index of Coexistent Disease; LTI = Lean Tissue Index; NODAT = 
New Onset Diabetes After Transplantation; Pre-DM = Pre-transplantation Diabetes Mellitus; SGA = Subjective Global Assessment. 


















































t = 0.73 




t = -0.16 
p = 0.07 
t = -0.40 
p < 0.001 
FTI 
BMI t = 0.19 
p = 0.11 
t = 0.06 
p = 0.50 
t = 0.89 
p < 0.001 
BMI 
Waist Circumference t = -0.31 
p = 0.09 
t = -0.16 
p = 0.18 
t = 0.71 
p < 0.001 
t = 0.87 
p < 0.001 






















*Low Muscle Strength, defined as HGS < Reference Cut-offs. 
** Low Muscle Mass, defined as LTI < Reference Cut-offs. 
***Sarcopenia, defined as both HGS and LTI < Reference Cut-offs. 
†Obesity, defined as fulfillment of ³ 2 out of 3 criteria from BMI ³ 30kg/m2, FTI > Reference Cut-offs, and Waist Circumference > WHO Cut-offs. 
††Sarcopenic Obesity, defined as a combination of sarcopenia and obesity. 
 










r = 0.25 





r = 0.67 
p < 0.001 
r = 0.59 
p < 0.001 
***Sarcopenia 
 
†Obesity r = 0.06 
p = 0.53 
r = 0.31 
p < 0.01 
r = 0.16 




r = 0.47 
p < 0.001 
r = 0.43 
p < 0.001 
r = 0.73 
p < 0.001 
r = 0.40 
p < 0.001 
Supplementary Material, Table 2a:  Univariate Associations of Muscular, Adiposity, and Composite Indices with the 
Risk of Mortality and Acute Hospitalisation 
 
 Univariate Cox Regression 
 
HR (95% CI) 
 
p-value 




0.95 (0.92, 0.97) <0.001 
LTI (kg/m2) 
 
0.92 (0.85, 0.99) 0.03 
BMI (kg/m2) 
 
1.01 (0.97, 1.06) 0.26 
FTI (kg/m2) 
 
1.03 (0.99, 1.07) 0.11 
Waist Circumference (cm) 
 
1.00 (0.99, 1.02) 0.42 
Categorical and Composite Indices 
 
aLow Muscle Strength 
 
3.81 (2.37, 6.11) <0.001 
bLow Muscle Mass 
 
1.06 (0.66, 1.71) 0.81 
cSarcopenia 
 
2.39 (1.41, 4.03) 0.001 
dObesity 
 
1.21 (0.79, 1.85) 0.17 
eSarcopenic Obesity 
 
2.67 (1.42, 5.02) 0.002 
 
aLow Muscle Strength, defined as HGS < Reference Cut-offs. 
bLow Muscle Mass, defined as LTI < Reference Cut-offs. 
cSarcopenia, defined as both HGS and LTI < Reference Cut-offs. 
dObesity, defined as fulfillment of ³ 2 out of 3 criteria from BMI ³ 30kg/m2, FTI > Reference Cut-offs, and Waist 
Circumference > WHO Cut-offs. 
eSarcopenic Obesity, defined as a combination of sarcopenia and obesity. 
 
Abbreviations:  BMI = Body Mass Index; CI = Confidence Interval; FTI = Fat Tissue Index; HR = Hazard Ratio; HGS = 



































Supplementary Material, Table 2b:  Univariate Associations between Covariates and the Risk of Mortality and Acute 
Hospitalisation 
 
 Univariate Cox Regression 
 
HR (95% CI) 
 
p-value 




1.05 (1.02, 1.09) 0.01 
Gender (Male) 
 
0.84 (0.53, 1.33) 0.45 
Ethnicity: 
Caucasian 
Non-Caucasian (Asian, Afro-Caribbean, and Others) 
 
 
0.54 (0.34, 0.94) 











1.29 (1.01, 1.71) 
3.56 (1.80, 7.06) 
 
<0.001 
Alcohol consumption (units/week) 
 













1.31 (0.69, 2.50) 
1.21 (0.60, 2.42) 
 
0.41 
Dialysis vintage (years) 
 
1.06 (1.01, 1.13) 0.03 
Pre-emptive transplantation 
 
0.82 (0.46, 1.48) 0.51 
Time post transplantation (years) 
 
1.10 (1.03, 1.19) 0.03 
Acute rejection episodes 
 
1.23 (0.59, 2.57) 0.59 
Immunosuppressive medications: 
CNI 




1.06 (0.49, 2.31) 
1.42 (0.68, 2.98) 





Use of statin 
 





0.99 (0.98, 1.01) 0.06 
hsCRP 
 
1.03 (1.01, 1.05) 0.04 
Hb (g/dL) 
 
0.81 (0.70, 0.93) 0.002 
Vitamin D (nmol/L) 
 
0.99 (0.98, 1.01) 0.11 




0.77 (0.61, 0.98) 0.04 
Physical activity level (hours/week) 
 
1.01 (0.96, 1.04) 0.24 
Protein intake (g/day) 
 
0.99 (0.98, 1.01) 0.81 
Energy intake (kcal/day) 
 
0.99 (0.98, 1.01) 0.82 
Abbreviations:  CI = Confidence Interval; CNI = calcineurin inhibitor; eGFR = estimated Glomerular Filtration Rate; Hb = 
Haemoglobin; HR = Hazard Ratio; hsCRP = high-sensitivity C-Reactive Protein; ICED = Index of Coexistent Disease; 
NODAT = New Onset Diabetes After Transplantation; Pre-transplantation DM = Pre-transplantation Diabetes Mellitus; 
SGA = Subjective Global Assessment. 
Supplementary Material, Table 3a:  Univariate Associations of Muscular, Adiposity, and Composite Indices with 
Physical Health-related Quality of Life 
 
 Univariate Linear Regression 
 
b (95% CI) 
 
p-value 




1.8 (1.3, 2.3) <0.001 
LTI (kg/m2) 
 
1.2 (0.6, 1.8) <0.001 
BMI (kg/m2) 
 
-0.1 (-0.9, 0.7) 0.67 
FTI (kg/m2) 
 
-0.3 (-1.0, 0.5) 0.40 
Waist Circumference (cm) 
 
-0.1 (-0.4, 0.1) 0.29 
Categorical and Composite Indices 
 
aLow Muscle Strength 
 
-16.1 (-25.4, -6.9) <0.001 
bLow Muscle Mass 
 
-10.9 (-20.1, -1.8) 0.01 
cSarcopenia 
 
20.6 (-32.1, -9.2) 0.001 
dObesity 
 
-5.8 (-13.7, 2.1) 0.15 
eSarcopenic Obesity 
 
-14.3 (-29.4, 0.7) 0.06 
 
aLow Muscle Strength, defined as HGS < Reference Cut-offs. 
bLow Muscle Mass, defined as LTI < Reference Cut-offs. 
cSarcopenia, defined as both HGS and LTI < Reference Cut-offs 
dObesity, defined as fulfillment of ³ 2 out of 3 criteria from BMI ³ 30kg/m2, FTI > Reference Cut-offs, and Waist 
Circumference > WHO Cut-offs. 
eSarcopenic Obesity, defined as a combination of sarcopenia and obesity. 
 
Abbreviations:  b = beta coefficient; BMI = Body Mass Index; CI = Confidence Interval; FTI = Fat Tissue Index; HGS = 



































Supplementary Material, Table 3b:  Univariate Associations of Muscular, Adiposity, and Composite Indices with 
Mental Health-related Quality of Life 
 
 Univariate Linear Regression 
 
b (95% CI) 
 
p-value 




1.4 (1.0, 1.8) <0.001 
LTI (kg/m2) 
 
1.7 (1.0, 2.5) 0.001 
BMI (kg/m2) 
 
0.6 (0.1, 1.1) 0.04 
FTI (kg/m2) 
 
0.2 (-0.4, 0.8) 0.50 
Waist Circumference (cm) 
 
0.1 (-0.2, 0.4) 0.19 
Categorical and Composite Indices 
 
aLow Muscle Strength 
 
-10.8 (-17.9, -2.6) 0.001 
bLow Muscle Mass 
 
-9.9 (-17.8, -2.1) 0.001 
cSarcopenia 
 
-14.2 (-23.2, -4.9) 0.01 
dObesity 
 
-6.2 (-15.8, 3.3) 0.18 
eSarcopenic Obesity 
 
-7.9 (-18.7, 2.5) 0.16 
 
aLow Muscle Strength, defined as HGS < Reference Cut-offs. 
bLow Muscle Mass, defined as LTI < Reference Cut-offs. 
cSarcopenia, defined as both HGS and LTI < Reference Cut-offs. 
dObesity, defined as fulfillment of ³ 2 out of 3 criteria from BMI ³ 30kg/m2, FTI > Reference Cut-offs, and Waist 
Circumference > WHO Cut-offs. 
eSarcopenic Obesity, defined as a combination of sarcopenia and obesity. 
 
Abbreviations:  b = beta coefficient; BMI = Body Mass Index; CI = Confidence Interval; FTI = Fat Tissue Index; HGS = 































Supplementary Material, Table 3c:  Univariate Associations between Covariates and Physical Health-related Quality 
of Life 
 
 Univariate Linear Regression 
 
b (95% CI) 
 
p-value 








-9.5 (-18.3, -0.6) <0.001 
Ethnicity: 
Caucasian 
















-8.0 (-17.8, 1.8) 




Alcohol consumption (units/week) 
 













-1.9 (-14.4, 10.5) 




Dialysis vintage (years) 
 
-0.6 (-1.8. 0.6) 0.32 
Pre-emptive transplantation 
 
-3.0 (-13.9, 7.8) 0.58 
Time post transplantation (years) 
 
-0.8 (-1.4, -0.1) 0.02 
Acute rejection episodes 
 
4.3 (-10.9, 19.4) 0.58 
Immunosuppressive medications: 
CNI 




7.1 (-8.0, 22.3) 
1.4 (-12.0, 14.8) 







Use of statin 
 





0.1 (-0.1, 0.4) 0.33 
hsCRP 
 
-0.1 (-0.7, 0.6) 0.92 
Hb (g/dL) 
 
3.2 (0.4, 6.1) 0.03 
Vitamin D (nmol/L) 
 
1.8 (0.4, 3.3) 
 
0.01 




4.9 (-0.5, 10.2) 0.08 
Physical activity level (hours/week) 
 
1.2 (0.3, 2.1) 0.01 
Protein intake (g/day) 
 
0.8 (-16.7, 18.2) 0.93 
Energy intake (kcal/day) 
 
-0.2 (-1.1, 0.6) 0.61 
Abbreviations:  b = beta coefficient; CI = Confidence Interval; CNI = calcineurin inhibitor; eGFR = estimated Glomerular 
Filtration Rate; Hb = Haemoglobin; hsCRP = high-sensitivity C-Reactive Protein; ICED = Index of Coexistent Disease; 
NODAT = New Onset Diabetes After Transplantation; Pre-transplantation DM = Pre-transplantation Diabetes Mellitus; 
SGA = Subjective Global Assessment. 
Supplementary Material, Table 3d:  Univariate Associations between Covariates and Mental Health-related Quality of 
Life 
 
 Univariate Linear Regression 
 
b (95% CI) 
 
p-value 








-9.2 (-16.9, -1.7) 0.02 
Ethnicity: 
Caucasian 















-9.5 (-17.9, -1.1) 





Alcohol consumption (units/week) 
 













-1.9 (-10.8, 6.9) 




Dialysis vintage (years) 
 
-0.4 (-1.4, 0.6) 0.46 
Pre-emptive transplantation 
 
-0.3 (-9.7, 9.1) 0.94 
Time post transplantation (years) 
 
-0.4 (-1.0, 0.1) 0.13 
Acute rejection episodes 
 
3.9 (-9.1, 17.1) 0.55 
Immunosuppressive medications: 
CNI 




5.1 (-7.9, 18.2) 
-1.0 (-12.6, 10.6) 






Use of statin 
 





0.1 (-0.2, 0.2) 0.80 
hsCRP 
 
-0.1 (-0.7, 0.4) 0.70 
Hb (g/dL) 
 
2.1 (-0.3, 4.6) 0.09 
Vitamin D (nmol/L) 
 
1.3 (0.1, 2.5) 0.04 




4.2 (-0.4, 8.8) 0.07 
Physical activity level (hours/week) 
 
0.8 (-0.1, 1.5) 0.06 
Protein intake (g/day) 
 
0.9 (-0.5, 2.4) 0.20 
Energy intake (kcal/day) 
 
0.1 (-0.7, 0.8) 0.82 
Abbreviations:  b = beta coefficient; CI = Confidence Interval; CNI = calcineurin inhibitor; eGFR = estimated Glomerular 
Filtration Rate; Hb = Haemoglobin; hsCRP = high-sensitivity C-Reactive Protein; ICED = Index of Coexistent Disease; 
NODAT = New Onset Diabetes After Transplantation; Pre-transplantation DM = Pre-transplantation Diabetes Mellitus; 
SGA = Subjective Global Assessment. 
